Table 2.

Pan Metabolic Severity Mapping of COVID-19 Severity—the top 25 most significant differentiating metabolites in the controls versus each severity group models for the integrated data set, ranked by fold change. The metabolites are colored according to the assay with which the metabolite is measured: lipids (black), lipoproteins (green), and the low molecular weight metabolites (magenta).

Rank	Control vs. B Severity	Control vs. C Severity	Control vs. D Severity	Control vs. E Severity
1	Pyruvic acid	Pyruvic acid	Pyruvic acid	Neopterin/tryptophan
2	Formic acid	Formic acid	Formic acid	Pyruvic acid
3	Asp:Glu/Asn:Gln	Asp:Glu/Asn:Gln	Asp:Glu/Asn:Gln	Formic acid
4	PC (16:0/18:2)	H4PL	H4A1	Asp:Glu/Asn:Gln
5	PC (18:1/18:2)	PC (18:1/18:2)	H4PL	TPA1
6	PC (20:0/20:4)	H4CH	H4A2	TPA2
7	HCER (22:0)	HCER.d (18:0/18:0)	PC (18:1/18:2)	H4A1
8	HCER.d (18:0/18:0)	PE.P (18:0/18:1)	H4CH	H4PL
9	PE.P (18:1/20:1)	PC (18:2/20:2)	PC (18:2/20:2)	H4A2
10	PC (18:2/20:2)	Lactate/pyruvate	LPC (20:0)	PC (18:1/18:2)
11	PE.P (18:0/20:1)	PE.P (18:0/22:5)	PE.P (18:0/22:5)	H4CH
12	LPC (18:2)	PE.O (16:0/18:1)	PE.P (16:0/22:5)	PC (18:0/20:1)
13	PE.P (18:0/20:4)	PE.P (16:0/20:1)	PE.P (16:0/20:4)	PE.P (18:0/22:5)
14	PE.O (18:0/22:5)	PE.P (16:0/22:5)	LPC (18:2)	PE.P (16:0/22:5)
15	PE.O (16:0/20:1)	LPC (18:2)	PE.P (18:1/20:4)	PC (20:0/20:3)
16	PE.P (18:1/18:2)	PE.P (18:0/20:4)	PE.P (18:1/18:2)	PE.P (16:0/20:4)
17	PC (18:2/18:3)	PE.O (16:0/20:1)	PC (18:2/18:3)	LPC (18:2)
18	PC (18:2/20:4)	PE.P (18:1/18:2)	PC (18:2/20:3)	PE.P (18:1/20:4)
19	PE.P (16:0/18:2)	PC (18:2/18:3)	PE.P (16:0/18:2)	PE.P (18:1/18:2)
20	PE.P (18:2/20:4)	PE.P (16:0/18:2)	PE.P (18:2/20:4)	PC (18:2/20:3)
21	PC (18:2/18:2)	PE.P (18:2/20:4)	PC (18:2/18:2)	PC (18:2/20:4)
22	PE.P (18:0/18:2)	PC (18:2/18:2)	PE.P (18:0/18:2)	PE.P (16:0/18:2)
23	PE.O (16:0/20:4)	PE.P (18:0/18:2)	PE.O (16:0/20:4)	PE.P (18:2/20:4)
24	PE.P (16:0/18:3)	PE.O (16:0/20:4)	PE.P (18:2/18:2)	PC (18:2/18:2)
25	PE.O (16:0/18:2)	PE.O (16:0/18:2)	PE.O (16:0/18:2)	PE.O (16:0/20:4)